PABLO MÍNGUEZ GABIÑA-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

    EJNMMI Physics, Vol. 10, Núm. 1

2021

  1. A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer

    Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403

  2. Dependency of the remnant 131I-NaI biokinetics on the administered activity in patients with differentiated thyroid cancer

    Physica Medica, Vol. 88, pp. 45-52

2020

  1. Feasibility and limitations of quantitative SPECT for 223Ra

    Physics in Medicine and Biology, Vol. 65, Núm. 8

2019

  1. Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11 GBq and 3.7 GBq of 131I-NaI respectively

    Physica Medica, Vol. 65, pp. 143-149

2018

  1. Comparison of microdosimetry-based absorbed doses to control tumours and clinically obtained tumour absorbed doses in treatments with 223Ra

    Physics in Medicine and Biology, Vol. 63, Núm. 14

  2. Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 1, pp. 20-27

2016

  1. Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131I-NaI treatments of differentiated thyroid cancer

    Medical Physics, Vol. 43, Núm. 10, pp. 5279-5287